Exact sciences corporation stock.

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.01-Nov-2023 ... MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...View live Exact Sciences Corporation chart to track its stock's price action. Find market predictions, EXAS financials and market news.Exact Sciences reported another quarter of strong growth, but screening sales missed whispered forecasts and EXAS stock plummeted Wednesday. The company is a leader in using diagnostics to screen ...

Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...About Exact Sciences Corp. ... 2022 and 2021. Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was zero for the three and six months ended June 30, 2022, compared to $2.4 million and $102.8 million for the three and six months …Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer (CRC) at 91% specificity, during the American College ...May 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...

Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Stock Information · Financial Information · SEC Filings · Quarterly Results · Analyst Coverage ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI ...Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ... Currently, Kevin T. Conroy occupies the position of Chairman, President & Chief Executive Officer at EXACT Sciences Corp. and President & Director at Genomic Health, Inc. (a subsidiary of EXACT Sciences Corp.). He is also on the board of 8 other companies. Kevin T. Conroy previously was Partner at McDermott Will & Emery LLP, Director at ...

Mar 2, 2023 · In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ...

Currently, Kevin T. Conroy occupies the position of Chairman, President & Chief Executive Officer at EXACT Sciences Corp. and President & Director at Genomic Health, Inc. (a subsidiary of EXACT Sciences Corp.). He is also on the board of 8 other companies. Kevin T. Conroy previously was Partner at McDermott Will & Emery LLP, Director at ...

Under the terms of the agreement, for each share of Genomic Health common stock they own, Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock ..."Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that …Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment. Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient.Exact Sciences Corporation Common Stock (EXAS) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating. Oct. 20.

Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ...SWAV stock has gained 41.4% so far this year. ShockWave Medical delivered an earnings surprise of 180.1%, on average, in the last four quarters. McKesson’s earnings per share estimates increased ...May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ... Exact Sciences Corporation (NasdaqCM:EXAS) acquired Sampleminded, Inc. for $7.6 million on August 1, 2017. Under the terms, Exact Sciences paid $3.2 million in cash and issued 0.09 million restricted stock units.EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …

Nov 13, 2023 · Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Analysts expect adjusted earnings to reach $-1.363 per share for the current fiscal year. Exact Sciences Corp does not currently pay a dividend.

Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...Stock EXAS November 21, 2023 NASDAQ 20 minutes delay ... At Exact Sciences, our mission is to eradicate cancer and the suffering it causes — through tests that help prevent it, detect it earlier ...Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ...Shares of medical diagnostic company Exact Sciences ( EXAS 1.49%) fell by a jaw-dropping 41% over the whole of 2021, according to data provided by S&P Global Market Intelligence. Although the ...

Dec 1, 2023 · Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact …Achieving some impressive results. Exact Sciences has already done well in growing its business. Sales of $1.8 billion in 2021 were double what the company generated in 2019 ($876 million).Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ... EXAS Exact Sciences Corp. Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ; Owners. Institutional Owners Retail Ownership Net Long/ ...EXACT Sciences Corporation stock price live 67.03, this page displays NASDAQ EXAS stock exchange data. View the EXAS premarket stock price ahead of the market session or assess the after hours quote.MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to ...26-Feb-2016 ... 26, 2016 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that, in support of the Company's continued growth plans, ...Feb 21, 2023 · MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022. Nov 1, 2023 · Exact Sciences Corp (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced on November 1, 2023, that the company generated revenue of $628.3 million for the third ... Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.

07-Oct-2020 ... What is Exact Sciences Corporation stock price? On 2023-12-01, Exact Sciences Corporation (EXAS-Q) stock closed at a price of $67.03.Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.The number of shares outstanding of the Registrant’s $0.01 par value Common Stock as of February 20, 2023 was178,217,142. ... EXACT SCIENCES CORPORATION ANNUAL REPORT ON FORM 10‑K YEAR ENDED DECEMBER 31, 2022 TABLE OF CONTENTS Page No. Part I Item 1. Business 4 Item 1A. Risk Factors 19Instagram:https://instagram. best semiconductor etfsrtx stock todaystock market octoberfidelity schwab Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ... hyreqdividend mmm EXACT Sciences Corp. Aktie Profil. Die EXACT Sciences Corp. Aktie wird unter der ISIN US30063P1057 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, Hannover, NASDAQ, Moskau ... online banks with digital debit cards Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.29-Jul-2019 ... ... share in a cash and stock transaction valued at $2.8 billion. The ... Corporation, 441 Charmany Drive, Madison, Wisconsin 53719, or by ...Exact Sciences Corporation is a leader in global cancer screening and diagnostics and is undertaking rapid global expansion through several new acquisitions. ... but confuses the stock analysts ...